Analytical Data
-
基因名
IL-6RA
-
简介
IL-6R alpha is a subunit alpha of IL-6 receptors, also shared by other interleukin receptors. IL-6R alpha acts as IL-6 agonist and involves in JAK/STAT, MAPK, and Akt signaling pathway[1][2]. IL-6R alpha/CD126, Human consists of 468 amino acids (M1-R468) with two fibronectin type-III-like domains contained in the N-terminal part (113-217 a.a, 218-316 a.a), and a soluble form (1-365 a.a). Soluble IL-6R (sIL-6R) binds IL-6 and dimerized gp130 to achieve trans signaling, and exhibits a tissue expression property in some immune systems. IL-6R alpha Protein, Human (L20-P365) is soluble form and expressed by CHO cells with a full length of the sequence of 346 amino acids.
- Application
-
生物活性
1. The ED50 is <0.2 μg/mL as measured by M1 cells. 2. Measured in a cell proliferation assay using TF-1 human erythroleukemic cells. The ED50 for this effect is 0.2113 ng/mL in the presence of 2 ng/mL recombinant mouse IL-6, corresponding to a specific activity is 4.73×106 units/mg. Measured in a cell proliferation assay using TF-1 human erythroleukemic cells. The ED50 for this effect is 0.2113 ng/mL in the presence of 2 ng/mL recombinant mouse IL-6, corresponding to a specific activity is 4.73×106units/mg.
-
别名
rHuIL-6R; IL-6RA; IL-6R 1; CD126; Membrane glycoprotein 80
-
种属
Human
-
表达系统
CHO
-
标签
Tag Free
-
纯度
> 90% as determined by SDS-PAGE.
-
蛋白编号
P08887
-
表达区间
L20-P365
-
氨基酸序列
LAPRRCPAQEVARGVLTSLPGDSVTLTCPGVEPEDNATVHWVLRKPAAGSHPSRWAGMGRRLLLRSVQLHDSGNYSCYRAGRPAGTVHLLVDVPPEEPQLSCFRKSPLSNVVCEWGPRSTPSLTTKAVLLVRKFQNSPAEDFQEPCQYSQESQKFSCQLAVPEGDSSFYIVSMCVASSVGSKFSKTQTFQGCGILQPDPPANITVTAVARNPRWLSVTWQDPHSWNSSFYRL
-
蛋白长度
Extracellular Domain
-
分子量
50-58 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interleukin-6 receptor alpha (IL-6RA) plays a pivotal role in the IL-6 signaling pathway, which is crucial for various physiological and pathological processes, including inflammation, immune response, and hematopoiesis. Elevated levels of IL-6 and its receptor have been implicated in several diseases, particularly autoimmune disorders, chronic inflammatory conditions, and even cancers. Consequently, IL-6RA has garnered significant attention as a therapeutic target for drug development. The research into recombinant IL-6RA proteins serves multiple purposes: they can be utilized in basic science to elucidate IL-6 signal transduction mechanisms, to develop novel therapeutic agents or as biomarkers for disease progression and treatment response. Additionally, recombinant IL-6RA proteins can be employed in preclinical and clinical studies to explore their potential in modulating the inflammatory response. By inhibiting IL-6 signaling, these engineered proteins may provide relief in patients with hyper-inflammatory conditions. Given the growing understanding of the role of IL-6 and its receptor in various diseases, research into IL-6RA recombinant proteins not only contributes to a deeper understanding of its biological function but also heralds advances in therapeutic strategies aimed at mitigating the detrimental effects of excessive IL-6 signaling. This research has broad implications for the treatment of diverse conditions, including rheumatoid arthritis, psoriasis, and other chronic inflammatory disorders, making it a highly relevant area within the fields of immunology and pharmacology.
